PREVENTIVE VACCINES MARKET ANALYSIS

Preventive Vaccines Market, By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, and Others), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, and Others), By Distribution Channel (Public and Private), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI5342
Pages :173
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges – High Cost of Vaccine Development

High cost of vaccine development is expected to hamper growth of the global preventive vaccines market. For instance, the cost of developing an epidemic infectious disease vaccine from preclinical trials through to end of phase 2a is US$ 31 million to 68 million assuming no risk of failure.

Market Opportunities – Increasing License Agreement among Key Market Players

Market players are focused on adopting organic growth strategies such as license agreement in order to expand their product portfolio. For instance, in September 2020, Shionogi & Co., Ltd., a pharmaceutical company, and HanaVax Inc., a drug-discovery venture company originating from the University of Tokyo, announced that they had entered into a license agreement for research, development, manufacturing, distribution, and commercialization of HanaVax’s Streptococcus pneumoniae nasal vaccine candidate.